DLP-208

**DLP-208** is a long-acting subcutaneous implant formulation of **tizanidine**, a centrally acting alpha-2 adrenergic agonist that reduces spasticity by increasing presynaptic inhibition of motor neurons and blocking nerve impulses to the brain. Developed by **Delpor, Inc.** using their proprietary Prozor or NANOPOR technology, it provides zero-order release kinetics for 3-6 months (potentially up to 6 months) via a minimally invasive 10-minute in-office abdominal implantation procedure, aiming to improve adherence, maintain steady therapeutic levels, and avoid peak-trough fluctuations of oral tizanidine (Zanaflex). Primarily indicated for moderate-to-severe spasticity associated with multiple sclerosis, cerebral palsy, traumatic brain injury, and spinal cord injury, it received a $2.5M NIH grant to advance to clinical testing.[1][2][4]